Table 1.
Demographic and clinical characteristics of the study group, depending on different types of disease-modifying therapy.
| Parameters | IFN-β1af | IFN-β1b | GAg | NTh | FGi | CGj | p |
|---|---|---|---|---|---|---|---|
| N | 22 | 17 | 5 | 7 | 12 | 10 | |
| Age [years] | 41.3 ± 11.7 | 44.8 ± 10.7 | 48.6 ± 12.4 | 33.9 ± 7.7 | 42.3 ± 13.9 | — | 0.27 |
| Age at the beginning of DMTa [years] | 38.8 ± 11.1 | 42.1 ± 10.8 | 46.4 ± 12.8 | 32.3 ± 7.9 | 40.7 ± 13.5 | 39.3 ± 3.5 | 0.38 |
| Age [% of females] | 68.2 | 82.4 | 60.0 | 85.7 | 58.3 | 60.0 | 0.62 |
| Time of MS [months] | 57.1 ± 30.8 | 85.8 ± 72.7 | 90.2 ± 31.3 | 81.6 ± 29.3 | 85.1 ± 33.3 | — | 0.14 |
| Time of DMT [months] | 29.6 ± 13.7 | 31.4 ± 15.1 | 26.0 ± 21.8 | 16.7 ± 6.5 | 18.7 ± 7.6 | — | 0.15 |
| EDSSb [score] | 2.5 ± 1.07 | 2.41 ± 0.87 | 2.60 ± 1.08 | 2.79 ± 1.11 | 3.08 ± 1.24 | — | 0.83 |
| ARRc [n] | 0.41 ± 0.59 | 0.35 ± 0.61 | 0.20 ± 0.45 | 0.00 ± ND | 0.50 ± 0.80 | — | 0.58 |
| T2 MRId lesions (from the time of diagnosis) [n] | 1.14 ± 0.47 | 1.18 ± 0.39 | 1.00 ± ND | 1.00 ± ND | 1.08 ± 0.29 | — | 0.76 |
| New MRI lesions (within the last year) [n] | 0.09 ± 0.29 | 0.06 ± 0.24 | 0.20 ± 0.45 | 0.00 ± ND | 0.33 ± 0.65 | — | 0.52 |
| Gd+e MRI lesions (from the time of diagnosis) [n] | 0.05 ± 0.21 | 0.12 ± 0.33 | 20.4 ± 45.1 | 0.00 ± ND | 0.83 ± 1.75 | — | 0.20 |
| New Gd+ MRI lesions (within the last year) [n] | 0.05 ± 0.21 | 0.06 ± 0.24 | 0.2 ± 0.45 | 0.00 ± ND | 0.83 ± 1.75 | — | 0.35 |
a: disease-modifying therapy; b: Expanded Disability Status Scale; c: annual relapse rate; d: magnetic resonance imaging; e: Gadovist; f: interferon beta; g: glatiramer acetate; h: natalizumab; i: fingolimod; j: control group.